Laurus Labs Reports 19% Increase in Q4 Profit to Rs 279 Crore Driven by CDMO Momentum

Laurus Labs Reports 19 Percent Rise in Net Profit for March Quarter

Laurus Labs, a leading contract development and manufacturing (CDMO) company, reported a 19 percent year-on-year (YoY) rise in net profit to Rs.279 crore for the March quarter. This growth was driven by strong execution in its CDMO business and continued margin expansion due to a better product mix.

The company announced a second interim dividend of Rs.1.20 per equity share, which represents 60 percent of the face value of Rs.2 per equity share. Revenue for the quarter rose 5 percent to Rs.1,812 crore, while EBITDA increased 10 percent to Rs.523 crore, lifting EBITDA margins to 28.9 percent from 27.7 percent a year earlier. Gross margins expanded sharply to 61.4 percent, reflecting a higher contribution from CDMO and improved operating leverage.

The CDMO division remained the key growth driver in the quarter, with revenues rising 20 percent year on year to Rs.589 crore, led by small-molecule projects and a sharp ramp-up in biologics, which more than doubled from a year earlier. Management said late-stage pipeline conversions and commercial API supplies continued to improve visibility.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

| Comparison of Financial Performance for Q4 FY26 | | --- | --- | --- | | Revenue | Q4 FY26 | Q4 FY25 | | (Rs. crore) | 1,812 | 1,726 | | % growth (YoY) | 5% | - | | EBITDA | 523 | 472 | | (Rs. crore) | | | | % growth (YoY) | 10% | - | | Gross Margins | 28.9% | 27.7% | | % growth (YoY) | - | - |

The affordable medicines business, which includes APIs and finished dosage formulations, reported a marginal 1 percent decline in quarterly revenues, weighed down by softness in formulations, though the API segment continued to post double-digit growth. The company said demand conditions in ARVs remained stable, even as it continued to diversify its revenue base.

For the full year FY26, Laurus Labs reported revenue of Rs.6,813 crore, EBITDA of Rs.1,826 crore and net profit of Rs.889 crore, marking year-on-year growth of 23 percent, 64 percent and 148 percent, respectively. The company said improved profitability translated into stronger cash generation, allowing it to reduce leverage even as it stepped up capital expenditure to support future growth across peptides, fermentation and advanced biologics platforms.

Looking ahead, management said a robust late-stage pipeline, expanding technology capabilities and ongoing investments position Laurus to sustain growth into FY27, while maintaining a focus on margins and balance-sheet strength.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline